drugset / Trial / NCT02484261
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Phase 1
Terminated
10 enrolled
Reuven Schore
Hyundai Hope On Wheels · collabMillennium Pharmaceuticals, Inc. · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This study aims to monitor patients for relapse of the leukemia following allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in order to identify patients early in relapse, with a low burden of disease, when interventions may be more successful by monitoring of peripheral blood lineage specific chimerism. Once disease has been confirmed, patients will initiate a novel combination of bortezomib and pravastatin.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-05-18
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Pravastatin | Small molecule | 10 mg | — |
| Subject | Pravastatin | Small molecule | 20 mg | — |
| Subject | Pravastatin | Small molecule | 40 mg | — |